Cannabis May Help Manage Lymphoma Treatment Symptoms
Interest in medical cannabis among people with lymphoma has grown, but the evidence supports a limited role: certain cannabinoid medicines may help relieve chemotherapy-related nausea and vomiting, while claims that cannabis can treat or control lymphoma remain unproven.
Lymphoma is a cancer of the lymphatic system, which includes the lymph nodes, spleen, thymus and bone marrow. The two broad categories are Hodgkin lymphoma and non-Hodgkin lymphoma, a diverse group of diseases with different causes, treatment strategies and prognoses. Risk varies by lymphoma type and may be influenced by age, sex, immune-system problems, family history and infections such as Epstein-Barr virus. The National Cancer Institute’s overview of Hodgkin lymphoma provides more detail on recognized risk factors and treatment.
Standard lymphoma treatment may include chemotherapy, radiation therapy, immunotherapy, targeted drugs or stem-cell transplantation. These treatments can cause side effects including nausea, vomiting, fatigue, appetite changes and pain. In this setting, cannabinoid medicines may have a supportive-care role rather than serving as a substitute for cancer treatment.
The strongest clinical evidence concerns chemotherapy-induced nausea and vomiting that has not responded adequately to standard anti-nausea medication. In the United States, the FDA-approved cannabinoid drugs dronabinol and nabilone can be used for this purpose. The National Cancer Institute notes that these medicines may be considered when conventional antiemetic treatment has failed, although they can cause side effects such as dizziness, sedation, euphoria or other changes in mood and perception. The NCI’s evidence summary on cannabis and cannabinoids describes the available research and its limitations.
Laboratory research has also produced interest in cannabinoids such as cannabidiol (CBD) and tetrahydrocannabinol (THC). For example, a study of CBD found that it inhibited several processes involved in blood-vessel formation in cell and animal models. That anti-angiogenesis study offers a possible explanation for why cannabinoids are being investigated in cancer research, but it does not show that CBD treats lymphoma in people. Findings from cells, laboratory animals or isolated tumor models cannot be assumed to predict the results of treatment in patients.
Research specifically evaluating cannabis as a lymphoma treatment remains limited. A 2024 clinical practice guideline from the American Society of Clinical Oncology concluded that clinicians should recommend against using cannabis or cannabinoids as a cancer-directed treatment outside a clinical trial. The guideline found that cannabinoids may help with refractory chemotherapy-induced nausea and vomiting when added to standard antiemetic care, but evidence for other cancer-related benefits remains uncertain. Read the ASCO guideline on cannabis and cannabinoids in adults with cancer.
Survival statistics also need to be interpreted carefully. Outcomes depend on the exact lymphoma subtype, stage, age, overall health and response to treatment. Recent U.S. data report five-year relative survival of approximately 89.3% for Hodgkin lymphoma and 74.3% for non-Hodgkin lymphoma, but these are population estimates—not predictions for an individual patient. SEER’s Hodgkin lymphoma statistics and SEER’s non-Hodgkin lymphoma statistics provide stage-specific context.
People receiving lymphoma treatment should discuss cannabis, CBD products and prescription cannabinoid medicines with their oncology team before using them. Products can differ substantially in strength and composition, and cannabinoids may cause sedation or interact with other medicines. Most importantly, cannabis should not replace chemotherapy, radiation, immunotherapy or other prescribed lymphoma treatment. For now, its best-supported use is symptom management—particularly difficult chemotherapy-related nausea and vomiting—while its potential anticancer effects remain an area for further research.
